Management of Sexually Transmitted Infections in Pregnancy

Öz

Sexually transmitted infections remain an important public health problem in developing countries. Since sexually transmitted infections are common especially in women in the reproductive age group, they are common during pregnancy and despite easy and effective algorithms for screening and treatment, they can still have serious consequences for women and newborns. Education, prevention, screening and treatment are the most important components in antenatal care of pregnant women who are in the high-risk group for these diseases. In this review, the importance and management of sexually transmitted infections in terms of pregnancy are evaluated.

Anahtar Kelimeler

• Sexually transmitted disease,fetus,pregnancy,newborn

Gebelikte Cinsel Yolla Bulaşan Hastalıkların Yönetimi

Öz

Cinsel yolla bulaşan enfeksiyonlar gelişmekte olan ülkelerde önemli bir halk sağlığı sorunu olmaya devam etmektedir. Cinsel yolla bulaşan enfeksiyonlar özellikle reprodüktif yaş grubundaki kadınlarda sık rastlanıldığı için gebelik sürecinde de ortaya çıkabilmekte ve tarama ve tedavi için kolay ve etkili algoritmalara rağmen hala kadınlar ve yenidoğanlar için ciddi sonuçlara neden olabilmektedirler. Eğitim, önleme, tarama ve tedavi bu hastalıklar için yüksek riskli gruba giren gebelerin antenatal bakımında en önemli unsurları oluşturmaktadır. Bu derlemede, cinsel yolla bulaşan enfeksiyonların gebelik açısından önemi ve yönetimini incelenmektedir.

Anahtar Kelimeler

• Cinsel yolla bulaşan hastalık,fetus,gebelik,yenidoğan

Kaynakça

1. 1. WHO, Global Health Sector Strategy on sexually transmitted infections 2016-2021 towards ending STIs. 2016: Geneva.
2. 2. Teasdale CA, Abrams EJ, Chiasson MA, Justman J, et al. Incidence of sexually transmitted infections during pregnancy. PLoS One. 2018; 13(5): p. e0197696.
3. 3. WHO Guidelines Approved by the Guidelines Review Committee, in WHO Guideline on Syphilis Screening and Treatment for Pregnant Women. 2017, World Health Organization Copyright (c) World Health Organization 2017: Geneva.
4. 4. Bowen V, Su J, Torrone E, Kidd S, et al. Increase in incidence of congenital syphilis - United States, 2012-2014. MMWR Morb Mortal Wkly Rep. 2015; 64(44): p. 1241-5.
5. 5. Satterwhite CL, Torrone E, Meites E, Dunne EF, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013; 40: 187-93.
6. 6. CDC. Sexually transmitted disease surveillance 2013. Atlanta: US Department of Health and Human Services; 2014.
7. 7. Alger LS, Lovchik JC, Heel JR, Blackmon LR, et al. The association of Chlamydia trachomatis, Neisseira gonorrhoeae, and group B streptococci with preterm rupture of the membranes and pregnancy outcome. Am J Obstet Gynecol. 1988; 159(2): 397-404.
8. 8. Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03): 1-137.

9. 9. LeFevre ML. USPSTF: screening for chlamydia and gonorrhea. Ann Intern Med. 2014; 161: 902-10.
10. 10. Costa MC, Bornhausen Demarch E, Azulay DR, Perisse AR, et al. Sexually transmitted diseases during pregnancy: a synthesis of particularities. An Bras Dermatol. 2010; 85: 767-82.
11. 11. Andrews WW, Goldenberg RL, Mercer B, Iams J, et al. The Preterm Prediction Study: association of second-trimester genitourinary Chlamydia infection with subsequent spontaneous preterm birth. Am J Obstet Gynecolo. 2000; 183; 662-8.
12. 12. LeFevre ML. USPSTF: screening for chlamydia and gonorrhea. Ann Intern Med 2014; 161: 902-10.
13. 13. Papp JR, Schachter J, Gaydos C, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep. 2014; 63(No. RR-02): 1-19.
14. 14. Geisler WM, Wang C, Morrison SG, Black CM, et al. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis. 2008; 35: 119-23.
15. 15. Jacobson GF, Autry AM, Kirby RS, Liverman EM, et al. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol. 2001; 184: 1352-4.
16. 16. Tosun S. Türkiye’de viral hepatit B Epidemiyolojisi Yayınların Metaanalizi, “Tabak F, Tosun S (eds). Viral Hepatit. Viral Hepatitle Savaşım Derneği Yayını, İstanbul Medikal Yayıncılık, İstanbul, 2013: 25-8.
17. 17. Mıstık R. Türkiye’de viral hepatit epidemiyolojisi - Yayınların irdelenmesi, “Tabak F, Balık İ, Tekeli E (eds). Viral Hepatit. Viral Hepatitle Savaşım Derneği Yayını, İstanbul Medikal Yayıncılık, İstanbul, 2007: 9-50.
18. 18. Sookoian S. Liver disease during pregnancy: acute viral hepatitis. Ann Hepatol 2006; 5:231. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985; 253: 1740.
19. 19. Centers for Disease Control and Prevention. HIV Surveillance Report. 2016; 28.
20. 20. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2012; 31: 1-235.
21. 21. Connor EM, Sperling RS, Gelber R, Kiselev P, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331: 1173-1180.
22. 22. Centers for Disease Control and Prevention (CDC) Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep. 1994; 43: 1-20.
23. 23. Brown ZA, Wald A, Morrow RA, Selke S, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003; 289: 203-9.
24. 24. Brown ZA, Benedetti J, Ashley R, Burchett S, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991; 324: 1247-52.
25. 25. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists. Management of herpes in pregnancy. ACOG Practice Bulletin No. 82. Obstet Gynecol. 2007; 109: 1489-98.
26. 26. Sheffield JS, Hollie LM, Hill JB, Stuart GS, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol. 2003; 102: 1396-403.
27. 27. Centers for Disease Control and Prevention. SexuallyTransmitted Diseases Treatment Guidelines. MMWR. 2006; 55: 1-94.
28. 28. Garland SM, Steben M, Sings HL, James M, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009; 199: 805-14.
29. 29. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecolo. 2003; 101(4): 645-52.
30. 30. Clifford GM, Gallus S, Herrero R, Munoz N, et al. Worldwide distribution ofHuman papillomavirus types in cytologically normalwomen in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366: 991-8.